April 3, 2017 / 4:34 PM / 4 months ago

BRIEF-Merrimack completes ONIVYDE sale to Ipsen

April 3 (Reuters) - Merrimack Pharmaceuticals Inc:

* Merrimack launches as new, refocused research & clinical development company with resources to advance prioritized lead pipeline candidates MM-121, MM-141 and MM-310

* Plans to return $140 million to stockholders through special cash dividend

* Merrimack received $575 million in cash upon closing Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below